ADAPY · CIK 0001621227
ADAPTIMMUNE THERAPEUTICS PLC
Annual figures as reported, FY2014–FY2024. Ratios and growth rates derived on-page.
Biological Products, (No Diagnostic Substances)
Company profile
Revenue
$178.0M
▲ +195.3% vs FY2023
Net income
−$70.8M
▲ +37.8% vs FY2023
Free cash flow
−$74.1M
▲ +49.1% vs FY2023
Diluted EPS
−$0.05
▲ +44.4% vs FY2023
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Jun ’25 quarter
$13.7M
▼ −89.3% vs Jun ’24
Net income — Jun ’25 quarter
−$30.3M
▼ −143.6% vs Jun ’24
Revenue — trailing 12 months
$65.1M
▼ −54.0% vs Jun ’24
Diluted EPS — trailing 12 months
−$0.11
▼ −83.3% vs Jun ’24
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Jun ’25 | $13.7M | −89.3% | — | −$30.3M | −221.8% | −$0.02 |
| Mar ’25 | $7.3M | 28.3% | — | −$47.6M | −653.2% | −$0.03 |
| Dec ’24 | $3.2M | 1294.8% | — | −$74.2M | −2303.4% | −$0.05 |
| Sep ’24 | $40.9M | 458.8% | — | −$17.6M | −43.1% | −$0.01 |
| Jun ’24 | $128.2M | 2399.6% | — | $69.5M | 54.2% | $0.04 |
| Mar ’24 | $5.7M | −88.1% | — | −$48.5M | −854.2% | −$0.03 |
| Dec ’23 | $231K | −97.9% | — | −$47.9M | −20743.3% | −$0.04 |
| Sep ’23 | $7.3M | 4.5% | — | −$45.6M | −623.0% | −$0.03 |
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Operating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedRevenue CAGR
+207.1%
3y
+175.5%
5y
+71.2%
10y
Share count change (split-adjusted)
+140.4%
5y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Op. margin | Net margin | FCF margin | ROE | ROA | Current ratio | Debt / equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | 100.0% | −38.6% | −39.8% | −41.6% | −597.6% | −28.8% | 2.92× | 4.58× |
| FY2023 | — | −231.8% | −188.9% | −241.5% | −288.2% | −40.3% | 2.85× | — |
| FY2022 | — | −604.0% | −609.5% | −630.9% | −202.1% | −50.3% | 3.96× | — |
| FY2021 | — | −2638.6% | −2571.0% | 35.0% | −76.8% | −33.7% | 6.64× | — |
| FY2020 | — | −3370.5% | −3286.8% | −1413.1% | −38.1% | −28.8% | 10.19× | — |
| FY2019 | — | −12457.2% | −12225.0% | −10169.3% | −110.9% | −75.6% | 3.51× | — |
| FY2018 | — | −138.4% | −160.5% | −182.0% | −38.7% | −34.5% | 9.46× | — |
| FY2017 | — | −213.2% | −185.4% | −208.7% | −34.6% | −24.9% | 3.10× | — |
| FY2016 | — | −512.7% | −504.1% | −420.3% | −43.1% | −30.5% | 4.94× | — |
| FY2015 | — | −249.6% | −223.5% | −352.0% | −8.5% | −7.3% | 11.02× | — |
| FY2014 | — | −1396.5% | −1406.2% | 4299.3% | −392.3% | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2024 | $178.0M | $178.0M | −$68.8M | −$70.8M | −$0.05 | −$73.2M | $886K | $246.0M | $234.1M | $11.8M | $91.1M | $54.3M |
| FY2023 | $60.3M | — | −$139.7M | −$113.9M | −$0.09 | −$140.9M | $4.7M | $282.6M | $243.1M | $39.5M | $144.0M | — |
| FY2022 | $27.1M | — | −$164.0M | −$165.5M | −$0.17 | −$141.8M | $29.5M | $328.9M | $247.0M | $81.9M | $108.0M | — |
| FY2021 | $6.1M | — | −$162.2M | −$158.1M | −$0.17 | $10.7M | $8.6M | $469.5M | $263.6M | $206.0M | $149.9M | — |
| FY2020 | $4.0M | — | −$133.4M | −$130.1M | −$0.15 | −$53.6M | $2.3M | $451.1M | $109.9M | $341.2M | $56.9M | — |
| FY2019 | $1.1M | — | −$139.8M | −$137.2M | −$0.22 | −$112.5M | $1.6M | $181.5M | $57.9M | $123.6M | $50.4M | — |
| FY2018 | $59.5M | — | −$82.4M | −$95.5M | −$0.16 | −$104.4M | $3.9M | $276.7M | $29.9M | $246.9M | $68.4M | — |
| FY2017 | $37.8M | — | −$80.7M | −$70.1M | −$0.13 | −$54.3M | $24.6M | $281.1M | $78.2M | $203.0M | $84.0M | — |
| FY2016 | $14.2M | — | −$72.8M | −$71.6M | −$0.17 | −$48.2M | $11.5M | $234.5M | $68.4M | $166.1M | $158.8M | — |
| FY2015 | $9.9M | — | −$24.6M | −$22.1M | −$0.17 | −$29.7M | $5.1M | $300.7M | $41.6M | $259.0M | $229.0M | — |
| FY2014 | $825K | — | −$11.5M | −$11.6M | −$0.08 | $36.8M | $1.4M | — | — | $3.0M | $51.2M | — |
Latest filings
the most recent regulatory filingsRWSEC filing2026-04-22 ↗SCHEDULE 13GSEC filing2026-02-17 ↗EFFECTSEC filing2025-11-14 ↗SCHEDULE 13G/ASEC filing2025-11-14 ↗424B3Prospectus2025-11-13 ↗15-12GSEC filing2025-11-13 ↗S-8 POSSecurities registration2025-10-28 ↗S-8 POSSecurities registration2025-10-28 ↗S-8 POSSecurities registration2025-10-28 ↗POS AMSEC filing2025-10-28 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.